Potencies of human immunodeficiency virus protease inhibitors in vitro against Plasmodium falciparum and in vivo against murine malaria

Antimicrobial Agents and Chemotherapy

Volumn 50, Issue 2, 2006, Pages 639-648

  Andrews, Katherine T ^a,b   Fairlie, David P ^b   Madala, Praveen K ^b   Ray, John ^c   Wyatt, David M ^d   Hilton, Petrina M ^a   Melville, Lewis A ^a   Beattie, Lynette ^a   Gardiner, Donald L ^a   Reid, Robert C ^b   Stoermer, Martin J ^b   Skinner Adams, Tina ^b   Berry, Colin ^d   McCarthy, James S ^a  

^a QIMR BERGHOFER MEDICAL RESEARCH INSTITUTE   (Australia)

^b UNIVERSITY OF QUEENSLAND   (Australia)

^c ST VINCENT S HOSPITAL   (Australia)

^d CARDIFF UNIVERSITY   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AMPRENAVIR; ANTIMALARIAL AGENT; ANTIRETROVIRUS AGENT; ASPARTIC PROTEINASE; ATAZANAVIR; ATOVAQUONE PLUS PROGUANIL; BR 124; BR 314; EH 58; FORTIVASE; LOPINAVIR; LOPINAVIR PLUS RITONAVIR; PEPSTATIN; PEPSTATIN DERIVATIVE; PLASMEPSIN I; PLASMEPSIN II; PLASMEPSIN IV; PROTEINASE INHIBITOR; RITONAVIR; RO 40 5576; SAQUINAVIR; TIPRANAVIR; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIMALARIAL ACTIVITY; ARTICLE; COMPUTER MODEL; CONTROLLED STUDY; DRUG POTENCY; ENDEMIC DISEASE; ENZYME INHIBITION; FEMALE; GEOGRAPHIC DISTRIBUTION; GROWTH INHIBITION; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LIGAND BINDING; MALARIA; MOUSE; NONHUMAN; PLASMODIUM CHABAUDI; PLASMODIUM FALCIPARUM; PRIORITY JOURNAL;

ANIMALS; ASPARTIC ENDOPEPTIDASES; BINDING SITES; CRYSTALLIZATION; FEMALE; HEMOGLOBINS; HIV PROTEASE INHIBITORS; MALARIA; MICE; MICE, INBRED C57BL; PLASMODIUM FALCIPARUM; PROTEIN CONFORMATION;

EID: 31944440918     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/AAC.50.2.639-648.2006     Document Type: Article

References (61)

1. Abbenante, G., and D. P. Fairlie. 2005. Protease inhibitors in the clinic. Med. Chem. 1:71-104.
2. Andrews, K. T., A. Walduck, M. J. Kelso, D. P. Fairlie, A. Saul, and P. G. Parsons. 2000. Anti-malarial effect of histone deacetylation inhibitors and mammalian tumour cytodifferentiating agents. Int. J. Parasitol. 30:761-768.
3. Asojo, O. A., S. V. Gulnik, E. Afonina, B. Yu, J. A. Ellman, T. S. Haque, and A. M. Silva. 2003. Novel uncomplexed and complexed structures of plasmepsin II, an aspartic protease from Plasmodium falciparum. J. Mol. Biol. 327:173-181.
4. Back, D. J., S. H. Khoo, S. E. Gibbons, and C. Merry. 2001. The role of therapeutic drug monitoring in treatment of HIV infection. Br. J. Clin. Pharmacol. 52:89S-96S.
5. Bailey, E., R. Jambou, J. Savel, and G. Jaureguiberry. 1992. Plasmodium falciparum: differential sensitivity in vitro to E-64 (cysteine protease inhibitor) and pepstatin A (aspartyl protease inhibitor). J. Protozool. 39:593-599.
6. Banerjee, R., J. Liu, W. Beatty, L. Pelosof, M. Klemba, and D. E. Goldberg. 2002. Four plasmepsins are active in the Plasmodium falciparum food vacuole, including a protease with an active-site histidine. Proc. of the Natl. Acad. Sci. USA 99:990-995.
7. Berry, C., M. J. Humphreys, P. Matharu, R. Granger, P. Horrocks, R. P. Moon, U. Certa, R. G. Ridley, D. Bur, and J. Kay. 1999. A distinct member of the aspartic proteinase gene family from the human malaria parasite Plasmodium falciparum. FEBS Lett. 447:149-154.
8. Boffito, M., D. Back, M. Stainsby-Tron, A. Hill, G. Di Perri, G. Moyle, M. Nelson, J. Tomkins, B. Gazzard, and A. Pozniak. 2005. Pharmacokinetics of saquinavir hard gel/ritonavir (1000/100 mg twice daily) when administered with tenofovir diproxil fumarate in HIV-1-infected subjects. Br. J. Clin. Pharmacol. 59:38-42.
9. Bohm, H. J. 1998. Prediction of binding constants of protein ligands: a fast method for the prioritization of hits obtained from de novo design or 3D database search programs. J. Comput. Aided Mol. Des. 12:309-323.
10. Bold, G., A. Fassler, H. G. Capraro, R. Cozens, T. Klimkait, J. Lazdins, J. Mestan, B. Poncioni, J. Rosel, D. Stover, M. Tintelnot-Blomley, F. Acemoglu, W. Beck, E. Boss, M. Eschbach, T. Hurlimann, E. Masso, S. Roussel, K. Ucci-Stoll, D. Wyss, and M. Lang. 1998. New aza-dipeptide analogues as potent and orally absorbed HIV-1 protease inhibitors: candidates for clinical development. J. Med. Chem. 41:3387-3401.
11. Bray, P. G., O. Janneh, K. J. Raynes, M. Mungthin, H. Ginsburg, and S. A. Ward. 1999. Cellular uptake of chloroquine is dependent on binding to ferriprotoporphyrin IX and is independent of NHE activity in Plasmodium falciparum. J. Cell Biol. 145:363-376.
12. Buss, N., P. Snell, J. Bock, A. Hsu, and K. Jorga. 2001. Saquinavir and ritonavir pharmacokinetics following combined ritonavir and saquinavir (soft gelatin capsules) administration. Br. J. Clin. Pharmacol. 52:255-264.
13. Coombs, G. H., and J. C. Mottram. 1997. Parasite proteinases and amino acid metabolism: possibilities for chemotherapeutic exploitation. Parasitology 114(Suppl.):S61-S80.
14. Dame, J. B., C. A. Yowell, L. Omara-Opyene, J. M. Carlton, R. A. Cooper, and T. Li. 2003. Plasmepsin 4, the food vacuole aspartic proteinase found in all Plasmodium spp. infecting man. Mol. Biochem. Parasitol. 130:1-12.
15. Egan, T. J., J. M. Combrinck, J. Egan, G. R. Hearne, H. M. Marques, S. Ntenteni, B. T. Sewell, P. J. Smith, D. Taylor, D. A. van Schalkwyk, and J. C. Walden. 2002. Fate of haem iron in the malaria parasite Plasmodium falciparum. Biochem. J. 365:343-347.
16. Elliott, S. R., R. D. Kuns, and M. F. Good. 2005. Heterologous immunity in the absence of variant-specific antibodies after exposure to subpatent infection with blood-stage malaria. Infect. Immun. 73:2478-2485.
17. Fidock, D. A., P. J. Rosenthal, S. L. Croft, R. Brun, and S. Nwaka. 2004. Antimalarial drug discovery: efficacy models for compound screening. Nat. Rev. Drug Discov. 3:509-520.
18. Francis, S. E., I. Y. Gluzman, A. Oksman, D. Banerjee, and D. E. Goldberg. 1996. Characterization of native falcipain, an enzyme involved in Plasmodium falciparum hemoglobin degradation. Mol. Biochem. Parasitol. 83:189-200.
19. Francis, S. E., I. Y. Gluzman, A. Oksman, A. Knickerbocker, R. Mueller, M. L. Bryant, D. R. Sherman, D. G. Russell, and D. E. Goldberg. 1994. Molecular characterization and inhibition of a Plasmodium falciparum aspartic hemoglobinase. EMBO J. 13:306-317.
20. Ginsburg, H. 1990. Some reflections concerning host erythrocyte-malarial parasite interrelationships. Blood Cells 16:225-235.
21. Gluzman, I. Y., S. E. Francis, A. Oksman, C. E. Smith, K. L. Duffin, and D. E. Goldberg. 1994. Order and specificity of the Plasmodium falciparum hemoglobin degradation pathway. J. Clin. Investig. 93:1602-1608.
22. Goldberg, D. E., A. F. Slater, R. Beavis, B. Chait, A. Cerami, and G. B. Henderson. 1991. Hemoglobin degradation in the human malaria pathogen Plasmodium falciparum: a catabolic pathway initiated by a specific aspartic protease. J. Exp. Med. 173:961-969.
23. Goldberg, D. E., A. F. Slater, A. Cerami, and G. B. Henderson. 1990. Hemoglobin degradation in the malaria parasite Plasmodium falciparum: an ordered process in a unique organelle. Proc. Natl. Acad. Sci. USA 87:2931-2935.
24. Hill, J., L. Tyas, L. H. Phylip, J. Kay, B. M. Dunn, and C. Berry. 1994. High level expression and characterisation of plasmepsin II, an aspartic proteinase from Plasmodium falciparum. FEBS Lett. 352:155-158.
25. Hsu, A., J. Isaacson, S. Brun, B. Bernstein, W. Lam, R. Bertz, C. Foit, K. Rynkiewicz, B. Richards, M. King, R. Rode, D. J. Kempf, G. R. Granneman, and E. Sun. 2003. Pharmacokinetic-pharmacodynamic analysis of lopinavir-ritonavir in combination with efavirenz and two nucleoside reverse transcriptase inhibitors in extensively pretreated human immunodeficiency virus-infected patients. Antimicrob. Agents Chemother. 47:350-359.
26. 50 in studies of drug resistance of malaria parasites. Acta Trop. 55:257-261.
27. Huisman, M. T., J. W. Smit, H. R. Wiltshire, R. M. Hoetelmans, J. H. Beijnen, and A. H. Schinkel. 2001. P-glycoprotein limits oral availability, brain, and fetal penetration of saquinavir even with high doses of ritonavir. Mol. Pharmacol. 59:806-813.
28. Kempf, D. J., K. C. Marsh, J. F. Denissen, E. McDonald, S. Vasavanonda, C. A. Flentge, B. E. Green, L. Fino, C. H. Park, X. P. Kong, et al. 1995. ABT-538 is a potent inhibitor of human immunodeficiency virus protease and has high oral bioavailability in humans. Proc. Natl. Acad. Sci. USA 92:2484-2488.
29. Kempf, D. J., K. C. Marsh, G. Kumar, A. D. Rodrigues, J. F. Denissen, E. McDonald, M. J. Kukulka, A. Hsu, G. R. Granneman, P. A. Baroldi, E. Sun, D. Pizzuti, J. J. Plattner, D. W. Norbeck, and J. M. Leonard. 1997. Pharmacokinetic enhancement of inhibitors of the human immunodeficiency virus protease by coadministration with ritonavir. Antimicrob. Agents Chemother. 41:654-660.
30. Lambros, C., and J. P. Vanderberg. 1979. Synchronization of Plasmodium falciparum erythrocytic stages in culture. J. Parasitol. 65:418-420.
31. Lee, B. J., A. Singh, P. Chiang, S. J. Kemp, E. A. Goldman, M. I. Weinhouse, G. P. Vlasuk, and P. J. Rosenthal. 2003. Antimalarial activities of novel synthetic cysteine protease inhibitors. Antimicrob. Agents Chemother. 47:3810-3814.
32. Lipinski, C. A., F. Lombardo, B. W. Dominy, and P. J. Feeney. 1997. Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Adv. Drug Deliv. Rev. 23:3-25.
33. Liu, J., I. Y. Gluzman, M. E. Drew, and D. E. Goldberg. 2005. The role of Plasmodium falciparum food vacuole plasmepsins. J. Biol. Chem. 280:1432-1437.
34. Marsh, K. 1998. Malaria disaster in Africa. Lancet 352:924.
35. Martins, T. M., C. Novo, V. E. do Rosario, and A. Domingos. 2003. Aspartic proteases from Plasmodium chabaudi: a rodent model for human malaria. Acta Trop. 89:1-12.
36. Musial, B. L., J. K. Chojnacki, and C. I. Coleman. 2004. Atazanavir: a new protease inhibitor to treat HIV infection. Am. J. Health Syst. Pharmacol. 61:1365-1374.
37. Nathoo, S., L. Serghides, and K. C. Kain. 2003. Effect of HIV-1 antiretroviral drugs on cytoadherence and phagocytic clearance of Plasmodium falciparum-parasitised erythrocytes. Lancet 362:1039-1041.
38. Omara-Opyene, A. L., P. A. Moura, C. R. Sulsona, J. A. Bonilla, C. A. Yowell, H. Fujioka, D. A. Fidock, and J. B. Dame. 2004. Genetic disruption of the Plasmodium falciparum digestive vacuole plasmepsins demonstrates their functional redundancy. J. Biol. Chem. 279:54088-54096.
39. Pagola, S., P. W. Stephens, D. S. Bohle, A. D. Kosar, and S. K. Madsen. 2000. The structure of malaria pigment beta-haematin. Nature 404:307-310.
40. Parikh, S., J. Gut, E. Istvan, D. E. Goldberg, D. V. Havlir, and P. J. Rosenthal. 2005. Antimalarial activity of human immunodeficiency virus type 1 protease inhibitors. Antimicrob. Agents Chemother. 49:2983-2985.
41. Ray, J., E. Pang, and D. Carey. 2002. Simultaneous determination of indinavir, ritonavir and lopinavir (ABT 378) in human plasma by high-performance liquid chromatography. J. Chromatogr. 775:225-230.
42. Roberts, N. A., J. A. Martin, D. Kinchington, A. V. Broadhurst, J. C. Craig, I. B. Duncan, S. A. Galpin, B. K. Handa, J. Kay, A. Krohn, et al. 1990. Rational design of peptide-based HIV proteinase inhibitors. Science 248:358-361.
43. Robinson, B. S., K. A. Riccardi, Y. F. Gong, Q. Guo, D. A. Stock, W. S. Blair, B. J. Terry, C. A. Deminie, F. Djang, R. J. Colonno, and P. F. Lin. 2000. BMS-232632, a highly potent human immunodeficiency virus protease inhibitor that can be used in combination with other available antiretroviral agents. Antimicrob. Agents Chemother. 44:2093-2099.
44. Rosenthal, P. J. 1995. Plasmodium falciparum: effects of proteinase inhibitors on globin hydrolysis by cultured malaria parasites. Exp. Parasitol. 80:272-281.
45. Rosenthal, P. J. 1999. Proteases of protozoan parasites. Adv. Parasitol. 43:105-159.
46. Rosenthal, P. J., J. H. McKerrow, M. Aikawa, H. Nagasawa, and J. H. Leech. 1988. A malarial cysteine proteinase is necessary for hemoglobin degradation by Plasmodium falciparum. J. Clin. Investig. 82:1560-1566.
47. Saliba, K. J., and K. Kirk. 1998. Uptake of an antiplasmodial protease inhibitor into Plasmodium falciparum-infected human erythrocytes via a parasite-induced pathway. Mol. Biochem. Parasitol. 94:297-301.
48. Savarino, A., R. Cauda, and A. Cassone. 2005. Aspartic proteases of Plasmodium falciparum as the target of HIV-1 protease inhibitors. J. Infect. Dis. 191:1381-1382.
49. Sham, H. L., D. J. Kempf, A. Molla, K. C. Marsh, G. N. Kumar, C. M. Chen, W. Kati, K. Stewart, R. Lal, A. Hsu, D. Betebenner, M. Korneyeva, S. Vasavanonda, E. McDonald, A. Saldivar, N. Wideburg, X. Chen, P. Niu, C. Park, V. Jayanti, B. Grabowski, G. R. Granneman, E. Sun, A. J. Japour, D. W. Norbeck, et al. 1998. ABT-378, a highly potent inhibitor of the human immunodeficiency virus protease. Antimicrob. Agents Chemother. 42:3218-3224.
50. Skinner-Adams, T. S., L. W. Guddat, D. L. Gardiner, J. S. McCarthy, and K. T. Andrews. 2005. Are Plasmodium falciparum plasmepsins the target of HIV protease inhibitors? J. Infect. Dis. 191:1382-1383.
51. Skinner-Adams, T. S., J. S. McCarthy, D. L. Gardiner, P. M. Hilton, and K. T. Andrews. 2004. Antiretrovirals as antimalarial agents. J. Infect. Dis. 190:1998-2000.
52. Stevenson, M. M., J. J. Lyanga, and E. Skamene. 1982. Murine malaria: genetic control of resistance to Plasmodium chabaudi. Infect. Immun. 38:80-88.
53. Sullivan, D. J., Jr., I. Y. Gluzman, and D. E. Goldberg. 1996. Plasmodium hemozoin formation mediated by histidine-rich proteins. Science 271:219-222.
54. Tacconelli, E., A. Savarino, F. De Bernardis, R. Cauda, and A. Cassone. 2004. Candidiasis and HIV-protease inhibitors: the expected and the unexpected. Curr. Med. Chem. Immunol. Endocr. Metab. Agents 4:49-59.
55. Trager, W., and J. B. Jensen. 1976. Human malaria parasites in continuous culture. Science 193:673-675.
56. Tyndall, J. D., R. C. Reid, D. P. Tyssen, D. K. Jardine, B. Todd, M. Passmore, D. R. March, L. K. Pattenden, D. A. Bergman, D. Alewood, S. H. Hu, P. F. Alewood, C. J. Birch, J. L. Martin, and D. P. Fairlie. 2000. Synthesis, stability, antiviral activity, and protease-bound structures of substrate-mimicking constrained macrocyclic inhibitors of HIV-1 protease. J. Med. Chem. 43:3495-3504.
57. Vacca, J. P., B. D. Dorsey, R. B. Levin, S. L. McDaniel, J. P. Vacca, J. P. Guare, P. L. Darke, J. A. Zugay, E. A. Emini, W. A. Schleif, J. C. Quintero, et al. 1994. L-735,524: the design of a potent and orally bioavailable HIV protease inhibitor. J. Med. Chem. 37:3443-3451.
58. Vernick, K. D., and A. P. Waters. 2004. Genomics and malaria control. N. Engl. J. Med. 351:1901-1904.
59. West, M. L., and D. P. Fairlie. 1995. Targeting HIV-1 protease: a test of drug-design methodologies. Trends Pharmacol. Sci. 16:67-75.
60. World Health Organization. 2002, posting date. Statistical annex. In The world health report: reducing risks, promoting healthy life. World Health Organization, Geneva, Switzerland. [Online.]
61. Wyatt, D. M., and C. Berry. 2002. Activity and inhibition of plasmepsin IV, a new aspartic proteinase from the malaria parasite, Plasmodium falciparum. FEBS Lett. 513:159-162.